



Advanced Molecular Diagnostic Systems

The Walter and Eliza Hall Biotechnology Centre,
4 Research Avenue,
La Trobe R&D Park,
Bundoora,
Victoria 3083

T: +61 (0)3 9345 2127
F: +61 (0)3 9345 2242

Wednesday 21st January 2009

The ASX Company Announcement's office:

Clarification of Media Report in Australian Financial Review 21st January 2009

Genera Biosystems notes the report by Tony Featherstone appearing in today's edition of the Australian Financial Review.

This report makes comment on Genera's cash position and capital raising intentions.

Genera advises that the comment made in the report that the company "intends to test the market for funds next month" is not correct. No decision has been made to raise capital either next month or at any other time. Genera wishes to confirm that as at 31st December 2008, the company had a cash balance of approximately \$2.5 million. In the event that the company does raise additional capital, it is not the current intention of the Board to raise funds through the issuance of ordinary shares at a price below the IPO issue price of 50 cents.

The Genera Board regularly reviews the company's cash position and funding requirements. A current priority is to actively pursue partnerships and licensing deals for the AmpaSand platform in selected jurisdictions which, upon completion, will provide the company with material upfront license fees and milestone payments that will further enhance the company's current cash position. Genera remains on track to achieve registration of PapType in Australasia and Europe by the end of the second quarter.

The board and management of Genera remains committed to executing its clear business plan and driving the company toward sustained profitability in a manner that seeks to preserve and build shareholder equity value.

About Genera Biosystems:

Genera Biosystems Limited (ASX: GBI) is a molecular diagnostics company that develops, manufactures and distributes advanced molecular diagnostic tests. Its first product, PapType™, a test which simultaneously detects and genotypes human papillomavirus, is on sale in Australia through Healthscope. International registrations are expected in 2009. The company has a development pipeline of products including novel tests for Chlamydia trachomatis, and Neisseria gonorrhoea.

Further details:

Mr. David Symons,
Non Executive Director,
0410 559 184

Dr Allen Bollands
CEO Genera Biosystems Limited
Telephone: +61 (0)423 943 600
E-mail: allen.bollands@generabiosystems.com